Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay

Suzy E Meijer,1,2 Olga Klebanov-Akopyn,3 Vera Pavlov,2,3 Shachar Laks,4 David Hazzan,4 Aviram Nissan,2– 4 Douglas Zippel3,4 1Department of Infectious Disease, Sourasky Medical Center, Tel Aviv, Israel; 2The Surgical Oncology Laboratory, Hadassah-Hebrew University Hospital, Jerusalem, Israel; 3The Su...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meijer SE, Klebanov-Akopyn O, Pavlov V, Laks S, Hazzan D, Nissan A, Zippel D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	breast cancer circulating tumor cells cancer biomarkers early detection predictive potential Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a7d67bf3332545f4b885849966b0b547
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a7d67bf3332545f4b885849966b0b547
record_format	dspace
spelling	oai:doaj.org-article:a7d67bf3332545f4b885849966b0b5472021-12-02T18:26:07ZDetection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay1179-1314https://doaj.org/article/a7d67bf3332545f4b885849966b0b5472021-11-01T00:00:00Zhttps://www.dovepress.com/detection-of-minimal-residual-disease-in-the-peripheral-blood-of-breas-peer-reviewed-fulltext-article-BCTThttps://doaj.org/toc/1179-1314Suzy E Meijer,1,2 Olga Klebanov-Akopyn,3 Vera Pavlov,2,3 Shachar Laks,4 David Hazzan,4 Aviram Nissan,2– 4 Douglas Zippel3,4 1Department of Infectious Disease, Sourasky Medical Center, Tel Aviv, Israel; 2The Surgical Oncology Laboratory, Hadassah-Hebrew University Hospital, Jerusalem, Israel; 3The Surgical Oncology Laboratory, The Chaim Sheba Medical Center, Ramat Gan, Israel; 4Department of General and Oncological Surgery – Surgery C, The Chaim Sheba Medical Center, Ramat Gan, IsraelCorrespondence: Douglas ZippelDepartment of General & Oncological Surgery-Surgery C, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, IsraelTel +972-3-530-2714Fax +972-3-5341562Email dov.zippel@sheba.health.gov.ilPurpose: Minimal residual disease (MRD) refers to micrometastases that are undetectable by conventional means and is a potential source of disease relapse. This study aimed to detect the presence of breast cancer (BC) biomarkers (MGB-1, MGB-2, CK-19, NY-BR-1) using real-time polymerase chain reaction (RT-PCR) in peripheral blood mononuclear cells (PBMC) of BC patients and the impact of a positive assay on clinical outcome.Patients and Methods: Patients in the analysis included females > 18 years of age with biopsy-proven carcinoma of the breast. A 10 mL sample of venous blood was obtained from 10 healthy controls and 25 breast cancer patients. Comparisons of peripheral blood markers were made with clinicopathological variables.Results: High-quality RNA was extracted from all samples with a mean RNA concentration of 224.8± 155.3 ng/μL. Each of the molecular markers examined was highly expressed in the primary breast tumors (n = 3, positive controls) with none of the markers detected in healthy negative controls. The NY-BR-1 marker was expressed in one (4%) patient with metastatic disease with no MGB-1 and MGB-2 detected in any sample derived from the study patients. The CK-19 marker was detected in 16 (64%) of the BC cases. No correlation was found between CK-19 expression and tumor stage (P = 0.07) or nodal status (P = 0.32). No correlation was identified in the BC patients between CK-19 expression and receptor status in the BC primary tumor.Conclusion: This study showed high expression of all 4 markers NY-BR-1, MGB-1, MGB-2 and CK-19 in the PBMCs derived from breast cancer patients. CK-19 was detected in 64% of the stage I–III cases operated with curative intent, the only recurrent events occurring in the CK-19-positive cases. Our data confirm the need to enhance techniques for detection of MRD, which may better predict patients at risk for relapse.Keywords: breast cancer, circulating tumor cells, cancer biomarkers, early detection, predictive potentialMeijer SEKlebanov-Akopyn OPavlov VLaks SHazzan DNissan AZippel DDove Medical Pressarticlebreast cancercirculating tumor cellscancer biomarkersearly detectionpredictive potentialNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 13, Pp 617-624 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer circulating tumor cells cancer biomarkers early detection predictive potential Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer circulating tumor cells cancer biomarkers early detection predictive potential Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Meijer SE Klebanov-Akopyn O Pavlov V Laks S Hazzan D Nissan A Zippel D Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay
description	Suzy E Meijer,1,2 Olga Klebanov-Akopyn,3 Vera Pavlov,2,3 Shachar Laks,4 David Hazzan,4 Aviram Nissan,2– 4 Douglas Zippel3,4 1Department of Infectious Disease, Sourasky Medical Center, Tel Aviv, Israel; 2The Surgical Oncology Laboratory, Hadassah-Hebrew University Hospital, Jerusalem, Israel; 3The Surgical Oncology Laboratory, The Chaim Sheba Medical Center, Ramat Gan, Israel; 4Department of General and Oncological Surgery – Surgery C, The Chaim Sheba Medical Center, Ramat Gan, IsraelCorrespondence: Douglas ZippelDepartment of General & Oncological Surgery-Surgery C, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, IsraelTel +972-3-530-2714Fax +972-3-5341562Email dov.zippel@sheba.health.gov.ilPurpose: Minimal residual disease (MRD) refers to micrometastases that are undetectable by conventional means and is a potential source of disease relapse. This study aimed to detect the presence of breast cancer (BC) biomarkers (MGB-1, MGB-2, CK-19, NY-BR-1) using real-time polymerase chain reaction (RT-PCR) in peripheral blood mononuclear cells (PBMC) of BC patients and the impact of a positive assay on clinical outcome.Patients and Methods: Patients in the analysis included females > 18 years of age with biopsy-proven carcinoma of the breast. A 10 mL sample of venous blood was obtained from 10 healthy controls and 25 breast cancer patients. Comparisons of peripheral blood markers were made with clinicopathological variables.Results: High-quality RNA was extracted from all samples with a mean RNA concentration of 224.8± 155.3 ng/μL. Each of the molecular markers examined was highly expressed in the primary breast tumors (n = 3, positive controls) with none of the markers detected in healthy negative controls. The NY-BR-1 marker was expressed in one (4%) patient with metastatic disease with no MGB-1 and MGB-2 detected in any sample derived from the study patients. The CK-19 marker was detected in 16 (64%) of the BC cases. No correlation was found between CK-19 expression and tumor stage (P = 0.07) or nodal status (P = 0.32). No correlation was identified in the BC patients between CK-19 expression and receptor status in the BC primary tumor.Conclusion: This study showed high expression of all 4 markers NY-BR-1, MGB-1, MGB-2 and CK-19 in the PBMCs derived from breast cancer patients. CK-19 was detected in 64% of the stage I–III cases operated with curative intent, the only recurrent events occurring in the CK-19-positive cases. Our data confirm the need to enhance techniques for detection of MRD, which may better predict patients at risk for relapse.Keywords: breast cancer, circulating tumor cells, cancer biomarkers, early detection, predictive potential
format	article
author	Meijer SE Klebanov-Akopyn O Pavlov V Laks S Hazzan D Nissan A Zippel D
author_facet	Meijer SE Klebanov-Akopyn O Pavlov V Laks S Hazzan D Nissan A Zippel D
author_sort	Meijer SE
title	Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay
title_short	Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay
title_full	Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay
title_fullStr	Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay
title_full_unstemmed	Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay
title_sort	detection of minimal residual disease in the peripheral blood of breast cancer patients, with a multi marker (mgb-1, mgb-2, ck-19 and ny-br-1) assay
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/a7d67bf3332545f4b885849966b0b547
work_keys_str_mv	AT meijerse detectionofminimalresidualdiseaseintheperipheralbloodofbreastcancerpatientswithamultimarkermgb1mgb2ck19andnybr1assay AT klebanovakopyno detectionofminimalresidualdiseaseintheperipheralbloodofbreastcancerpatientswithamultimarkermgb1mgb2ck19andnybr1assay AT pavlovv detectionofminimalresidualdiseaseintheperipheralbloodofbreastcancerpatientswithamultimarkermgb1mgb2ck19andnybr1assay AT lakss detectionofminimalresidualdiseaseintheperipheralbloodofbreastcancerpatientswithamultimarkermgb1mgb2ck19andnybr1assay AT hazzand detectionofminimalresidualdiseaseintheperipheralbloodofbreastcancerpatientswithamultimarkermgb1mgb2ck19andnybr1assay AT nissana detectionofminimalresidualdiseaseintheperipheralbloodofbreastcancerpatientswithamultimarkermgb1mgb2ck19andnybr1assay AT zippeld detectionofminimalresidualdiseaseintheperipheralbloodofbreastcancerpatientswithamultimarkermgb1mgb2ck19andnybr1assay
_version_	1718378056605761536

Detection of Minimal Residual Disease in the Peripheral Blood of Breast Cancer Patients, with a Multi Marker (MGB-1, MGB-2, CK-19 and NY-BR-1) Assay

Ejemplares similares